Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Genedrive PLC RNS Release

Trading update


RNS Number : 0585C
Genedrive PLC
17 January 2018
 

For release: 17 January 2018

 

genedrive plc ("genedrive" or the "Company")

 

Trading Update

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today provides an unaudited period end update for the six months ended 31 December 2017.

 

Group revenue was £2.6m (2016: £2.8m) with diagnostic (Genedrive®) related revenue of £1.3m (2016: £1.2m).  Diagnostic revenue was largely comprised of the US Department of Defense project, with £1.0m of development income and £0.3m of product related sales.

 

genedrive has made significant strategic and operational progress in the period with the CE marking of its Genedrive® HCV ID Kit, the appointment of its distribution partner, Sysmex Corporation ("Sysmex"), in the EMEA and Asia Pacific regions, and the launch of the Hepatitis C test in Africa.  Recently published field study results also demonstrated the robust performance of the HCV test in a third party setting and on territory specific samples. The Company continues to make good progress towards commercialising its Genedrive® HCV ID test and is performing in line with current expectations.

 

The Services division generated revenue of £1.3m (2016: £1.7m).  While a disposal has yet to be secured in line with our strategic objective, discussions are ongoing and we remain optimistic that an appropriate divestment can be secured.

 

The Company closed the period with cash of £4.6m (30 June 2017: £5.1m), following the receipt of £1.2m R&D tax credits in the period.

 

David Budd, Chief Executive Officer of genedrive plc, said: " We are making good progress with the launch of the CE-marked Genedrive® HCV ID kit.  This is an exciting period of growth and evolution for genedrive as we transition to a commercial stage point of care diagnostics company." 

 

The Company expects to release results for the six months up to 31 December 2017 on 20 March 2018. 

-  Ends  -

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                              +44 (0)161 989 0245

Matthew Fowler: CFO

 

 

Peel Hunt LLP

James Steel                                                                                                                        +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

[email protected]  

 

 

Notes to Editors

 

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF assay has been launched in India and a Genedrive® HCV test has received CE-IVD Certification and has been launched in Africa. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and Asia Pacific regions.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com  

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTMMGMMNVVGRZM

Genedrive PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use